ArticleDiscover oncology2025
Analysis of clinicopathological features, treatment modalities, and survival outcomes in advanced gastric and colorectal signet ring cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced gastric and colorectal signet ring cell carcinoma (SRCC) exhibit distinct biological behaviors, yet comprehensive characterization of their clinicopathological features, treatment modalities, and survival disparities remains limited. Leveraging the Surveillance, Epidemiology, and End Results (SEER) database, this population-based study aimed to elucidate these critical aspects.
methodsWe retrospectively analyzed 15,214 patients with American Joint Committee on Cancer (AJCC) stage III/IV gastric (n = 10,203) or colorectal (n = 5011) SRCC diagnosed between 2000 and 2021. Clinicopathological characteristics and survival outcomes were compared across cohorts. Four treatment modalities were evaluated: surgery alone, chemotherapy (CT) alone, surgery + CT, and no therapy. Kaplan-Meier analysis and Cox proportional hazards regression were used to assess overall survival (OS) and cancer-specific survival (CSS).
resultsDeclining incidence trends were observed for both malignancies. CT alone was the most frequent treatment in gastric SRCC (39.3%), whereas surgery + CT predominated in colorectal SRCC (47.5%). Colorectal SRCC demonstrated significantly superior OS (HR: 0.62, 95% CI: 0.60-0.65, P < 0.001) and CSS (HR: 0.62, 95% CI: 0.60-0.65, P < 0.001) compared to gastric SRCC across all stratified subgroups. The 5-year OS/CSS rates were 6.3%/7.7% for gastric vs. 18.2%/23.0% for colorectal SRCC. Surgery + CT was associated with improved OS and CSS in both gastric and colorectal cohorts, regardless of AJCC stage III/IV. Multivariate analysis identified age, primary site, stage, treatment, and marital status as independent prognosticators.
conclusionsThis study highlights significant clinicopathological and prognostic heterogeneity between advanced gastric and colorectal SRCC, with colorectal tumors demonstrating more favorable outcomes. Surgery + CT may improve survival, highlighting the need for personalized treatment strategies based on the primary tumor site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.